Late-onset Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the gradual accumulation of specific neuropathologies, including beta amyloid and hyperphosphorylated tau proteins, followed by widespread brain atrophy and cognitive decline (Rombouts et al., 2000; Lerch et al., 2005, 2008). This evidence concerns the gene MAPT and Alzheimer disease.